• Register
  • Login

Iranian Journal of Child Neurology

  • Home
  • About
    • About the Journal
    • Indexing & Abstracting
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Current
  • Archives
  • Announcements
Advanced Search
  1. Home
  2. Archives
  3. Vol. 19 No. 3 (2025): Summer
  4. Research Article

Vol. 19 No. 3 (2025)

June 2025

Pediatric-Onset Neuromyelitis Optica Spectrum Disorder in Isfahan: Insights from a Cross-Sectional Study

  • Masoud Etemadifar
  • Mehri Salari
  • Mahdi Norouzi

Iranian Journal of Child Neurology, Vol. 19 No. 3 (2025), 25 June 2025 , Page 31-34
https://doi.org/10.22037/ijcn.v19i3.46733 Published: 2025-06-25

  • View Article
  • Download
  • Cite
  • References
  • Statastics
  • Share

Abstract

Objectives:

Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune demyelinating disease of the central nervous system. While NMOSD predominantly affects adults, pediatric-onset NMOSD (PONMOSD) cases are increasingly recognized, necessitating a better understanding of the disease in this population. This study aims to provide a comprehensive insight into the manifestations and management of PONMOSD.

Material & Methods:

This study was conducted at the Isfahan MS Clinic, Iran, recruiting 182 NMOSD patients between March 2021 and March 2022. Board-certified neurologists performed diagnosis and examination, applying the 2015 NMOSD diagnostic criteria. Clinical data were collected and analyzed, including demographic information, onset symptoms, family history, treatment, and MRI findings.

Results:

Eighteen patients with PONMOSD (9.9% of the total) were identified. The study cohort had a female-to-male ratio 2.6:1, with the most common onset symptoms being optic neuritis (ON) and transverse myelitis (TM). AQP4-Ab was positive in 66.7% of the patients, with longitudinally extensive transverse myelitis (LETM) being the most common MRI finding. Azathioprine and Rituximab were the most commonly used treatments in patients, respectively. Treatment response was generally favorable, with most patients responding to therapy.

Conclusion:

The present study provides valuable insights into the clinical characteristics and management of pediatric-onset NMOSD. Despite challenges in diagnosis and treatment, early recognition and appropriate management strategies can lead to improved outcomes in this population. Further research is needed to optimize diagnostic criteria and therapeutic approaches for pediatric NMOSD.

Keywords:
  • Pediatric-onset NMOSD
  • NMOSD
  • CNS demyelinating disease
  • Neuromyelitis Optica spectrum Disorder
  • pdf

How to Cite

Etemadifar, M., Salari, M., & Norouzi, M. (2025). Pediatric-Onset Neuromyelitis Optica Spectrum Disorder in Isfahan: Insights from a Cross-Sectional Study. Iranian Journal of Child Neurology, 19(3), 31–34. https://doi.org/10.22037/ijcn.v19i3.46733
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

References

Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015 Jul 14;85(2):177–89.

Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG. The spectrum of neuromyelitis optica. Lancet Neurol. 2007 Sep;6(9):805–15.

Hor JY, Asgari N, Nakashima I, Broadley SA, Leite MI, Kissani N, et al. Epidemiology of Neuromyelitis Optica Spectrum Disorder and Its Prevalence and Incidence Worldwide. Front Neurol. 2020;11:501.

Tillema JM, McKeon A. The spectrum of neuromyelitis optica (NMO) in childhood. J Child Neurol. 2012 Nov;27(11):1437–47.

Tenembaum S, Chitnis T, Nakashima I, Collongues N, McKeon A, Levy M, et al. Neuromyelitis optica spectrum disorders in children and adolescents. Neurology. 2016 Aug 30;87(9 Suppl 2):S59-66.

Marignier R, Hacohen Y, Cobo-Calvo A, Pröbstel AK, Aktas O, Alexopoulos H, et al. Myelin-oligodendrocyte glycoprotein antibody-associated disease. Lancet Neurol. 2021 Sep;20(9):762–72.

Absoud M, Lim MJ, Appleton R, Jacob A, Kitley J, Leite MI, et al. Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features: Table 1. J Neurol Neurosurg Psychiatry. 2015 Apr;86(4):470–2.

Paolilo RB, Paz JA da, Apóstolos-Pereira SL, Rimkus C de M, Callegaro D, Sato DK. Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents. Arq Neuropsiquiatr. 2023 Mar 22;81(2):201–11.

Ketelslegers IA, Catsman-Berrevoets CE, Neuteboom RF, Boon M, van Dijk KGJ, Eikelenboom MJ, et al. Incidence of acquired demyelinating syndromes of the CNS in Dutch children: a nationwide study. J Neurol. 2012 Sep;259(9):1929–35.

Cabrera-Gómez JA, Kurtzke JF, González-Quevedo A, Lara-Rodríguez R. An epidemiological study of neuromyelitis optica in Cuba. J Neurol. 2009 Jan;256(1):35–44.

McKeon A, Lennon VA, Lotze T, Tenenbaum S, Ness JM, Rensel M, et al. CNS aquaporin-4 autoimmunity in children. Neurology. 2008 Jul 8;71(2):93–100.

BAGHBANIAN SM, SAHRAIAN MA, NASER MOGHADASI A, ASGARI N. Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder: A Case Series from Iran. Iran J Child Neurol. 2019;13(3):99–104.

Chitnis T, Ness J, Krupp L, Waubant E, Hunt T, Olsen CS, et al. Clinical features of neuromyelitis optica in children. Neurology. 2016 Jan 19;86(3):245–52.

Kim HJ, Paul F, Lana-Peixoto MA, Tenembaum S, Asgari N, Palace J, et al. MRI characteristics of neuromyelitis optica spectrum disorder: an international update. Neurology. 2015 Mar 17;84(11):1165–73.

Camera V, Messina S, Elhadd KT, Sanpera-Iglesias J, Mariano R, Hacohen Y, et al. Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders. J Neurol Neurosurg Psychiatry. 2022 Jan;93(1):101–11.

  • Abstract Viewed: 218 times

Download Statastics

  • Linkedin
  • Twitter
  • Facebook
  • Google Plus
  • Telegram

Developed By

Open Journal Systems
  • Home
  • Archives
  • Submissions
  • About the Journal
  • Editorial Team
  • Contact
Powered by OJSPlus